4-HO-MET
4-HO-MET (metocin) is a synthetic psychedelic tryptamine and close structural analogue of psilocin, the active compound in magic mushrooms, producing broadly similar effects. It is not federally scheduled by name in the US but can be prosecuted as a psilocin analogue under the Federal Analogue Act, and some states have scheduled it explicitly.
Overview
4-HO-MET, also known as metocin or methylcybin, is a synthetic psychedelic of the tryptamine family, first made by Alexander Shulgin in the 1970s and described in his book TiHKAL. It is a close structural relative of psilocin (the compound psilocybin converts to in the body), and users report a broadly psilocybin-like experience. It emerged as a research-chemical / designer drug in the late 2000s and is typically sold as a powder or pellet.
Source: Wikipedia (CC-BY-SA); peer-reviewed literature (NIH/PMC)
Chemistry & mechanism of action
4-HO-MET is a non-selective serotonin receptor agonist that acts on the 5-HT2A receptor, the target central to classic psychedelics such as psilocin and LSD. Activating 5-HT2A produces the characteristic changes in perception, thought, and mood. Because it is structurally close to psilocin, its pharmacology and subjective effects are broadly comparable, though it has been far less studied.
Source: peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)
Effects
Reported effects resemble psilocybin: visual distortions, shifts in mood and thought, emotional openness, and altered sense of time, lasting several hours. Accounts describe experiences that can swing between euphoric and deeply unpleasant. Because it is obscure and little-studied, there is limited reliable information on its effects, and unregulated products vary in strength and identity.
Source: peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)
Risks & harms
Because 4-HO-MET has only a short history of human use and almost no formal safety research, its risk profile is poorly characterized — an uncertainty that is itself a hazard. As a serotonergic psychedelic it can produce intensely distressing psychological experiences, especially in an unsafe setting or for people vulnerable to psychiatric illness, and it may raise heart rate and blood pressure. Combining it with other serotonergic drugs — including certain antidepressants (SSRIs, MAOIs), other psychedelics, or stimulants like MDMA — carries a risk of serotonin syndrome, a potentially life-threatening reaction with agitation, high fever, rigidity, and rapid heart rate. Unregulated products cannot be assumed to contain what they claim or at the potency assumed; substances sold as one tryptamine are frequently another, and dose cannot be judged by eye. Anyone experiencing a severe psychiatric crisis, very high temperature, rigidity, or seizures needs emergency care — call 911, and Poison Control at 1-800-222-1222 can advise. This page has not yet been medically reviewed.
Source: peer-reviewed literature (NIH/PMC); SAMHSA; Wikipedia (CC-BY-SA)
Legal status (US)
In the United States, 4-HO-MET is not scheduled by name under the federal Controlled Substances Act. However, because it is a close structural analogue of psilocin — a Schedule I substance — it can be treated as a Schedule I controlled substance under the Federal Analogue Act when intended for human consumption, exposing possession, sale, or distribution to federal prosecution. Some states (such as South Dakota and West Virginia) have scheduled it explicitly or restricted synthetic tryptamines broadly. Legal status varies internationally. Follow local law; consult DEA resources for specifics. This page has not yet been medically reviewed.
Source: DEA; US federal law (Federal Analogue Act, 21 U.S.C. 813); Wikipedia (CC-BY-SA)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling — penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authorityand your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulatein the destination immediately — notthe destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With psychedelics, fear and confusion are usually temporary. Change your surroundings — calmer light, quiet music, a trusted person — and remind yourself it will lift as the drug wears off.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown — pending review”Identity
- PubChem CID
- 21786582PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-olPubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C13H18N2OPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CCN(C)CCC1=CNC2=C1C(=CC=C2)OPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- ORWQBKPSGDRPPA-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- metocin, 4-Hydroxy MET, COLOUR, METHYLCYBIN, METOCIN, ORWQBKPSGDRPPA-UHFFFAOYSA-N, US20240317683, Compound 6PubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
- Route
- Unknown — pending review
- Shape
- Unknown — pending review
- Color
- Unknown — pending review
- Imprint
- Unknown — pending review
- Score
- Unknown — pending review
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown — pending review
Dosage
Pending medical reviewer
